PI3K inhibition has also been tested, although the combination of the PI3K inhibitor BYL719 and pan-PIM inhibitor LGH447 in RRMM was poorly tolerated in a phase 1 study, with 26.7% of patients experiencing grade 3 or 4 thrombocytopenia, prompting premature termination (50). This evidence concerns the gene PIM1 and Thrombocytopenia.